Jazz Pharmaceuticals PLC

JAZZ Healthcare Biotechnology

Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 126.0%, free cash flow grew 141.0% and total debt fell 18.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

210.05 4.37 −2.04%
Market cap
$13.9B
P/E
13.8×
Fwd P/E
17.3×
Dividend yield
—
F-score
5/9
Altman Z
1.37
Beneish M
−3.03
Dividend safety
n/a

Jazz Pharmaceuticals PLC (JAZZ) P/E ratio

Alert me on P/E ratio

As of 16 October 2026, Jazz Pharmaceuticals PLC (JAZZ) trades at a P/E ratio of 13.8×. Over the past ten years it has ranged from 0.0× (March 2026) to 522× (June 2026); the current reading is higher than 29% of that period. That is above the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 13.5× (30.24%)
FY2023 19.4× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 38.3× 136.52%
FY2019 16.2× (2.56%)
FY2018 16.6× (1.68%)
FY2017 16.9× (2.35%)
FY2016 17.3× (33.75%)

Quarterly newest first

Period P/E ratio Change
Jun 2026 15.8× (96.16%)
Mar 2026 411× —
Dec 2025 0.0× —
Sep 2025 0.0× —
42 more quarters

Against its own ten years

Low 0.0× High 522×
Ten-year median 18.4×
Current reading's percentile 9

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on JAZZ